SCHEDULE: Vanguard Discloses 5.21% Stake in Halozyme Therapeutics

Vanguard Capital Management has reported beneficial ownership of 5.21% of Halozyme Therapeutics' common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, now beneficially owns 6,173,547 shares of Halozyme Therapeutics' common stock.
• This holding represents 5.21% of the total class of securities.
• Vanguard Capital Management has sole voting power over 902,329 shares and sole dispositive power over 6,173,547 shares.
• The filing indicates that Vanguard funds and other managed accounts have the right to receive dividends and proceeds from the sale of these securities, with no single other person holding more than a 5% interest.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating significant institutional interest from a major player like Vanguard, but without specific operational or financial performance data.

Positives

• Vanguard's significant stake suggests confidence in Halozyme Therapeutics' long-term prospects.
• The filing confirms that Vanguard manages a substantial portion of its holdings, indicating active investment management.

Future Outlook

This filing is a disclosure of ownership and does not contain forward-looking statements or guidance from Halozyme Therapeutics.

Industry Context

StockSavvy.ai notes that significant institutional ownership, such as that reported by Vanguard, often signals a degree of stability and investor confidence in a company's market position and future potential within the biotechnology sector.

Stakeholder Impact

• Shareholders: The filing indicates continued significant institutional support from Vanguard, which may be viewed positively by other shareholders.
• Management: The presence of a large, stable institutional investor like Vanguard can provide a degree of accountability and long-term focus.
• Creditors: No direct impact on creditors is indicated by this ownership filing.

Next Steps

• Vanguard will continue to hold and manage its investment in Halozyme Therapeutics.
• Halozyme Therapeutics will continue its business operations as disclosed in its other filings.

Key Dates

Keywords

Halozyme Therapeutics, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management